{"id":"enalapril-and-carvedilol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enalapril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that decreases heart rate, contractility, and peripheral vascular resistance. Together, they provide complementary cardiovascular protection in heart failure and hypertension.","oneSentence":"This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:22.310Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Post-myocardial infarction management"}]},"trialDetails":[{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT03071653","phase":"PHASE2","title":"Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study","status":"SUSPENDED","sponsor":"University of Cape Town","startDate":"2016-11-24","conditions":"Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy","enrollment":30},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT01557140","phase":"PHASE4","title":"A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2003-05","conditions":"Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy","enrollment":42},{"nctId":"NCT01110824","phase":"PHASE3","title":"Prevention of Left Ventricular Dysfunction During Chemotherapy","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-04","conditions":"Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Neoplasm","enrollment":90},{"nctId":"NCT00391846","phase":"PHASE4","title":"Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-10","conditions":"Heart Failure, Ventricular Dysfunction, Left","enrollment":252},{"nctId":"NCT00292162","phase":"NA","title":"Curing Atrial Fibrillation in Heart Failure","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2007-01","conditions":"Chronic Heart Failure, Atrial Fibrillation","enrollment":41},{"nctId":"NCT00295542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2000-03","conditions":"Hypertension","enrollment":3344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Enalapril and carvedilol","genericName":"Enalapril and carvedilol","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol). Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}